ClinicalTrials.gg
WithdrawnNCT01055600Updated May 13, 2015

Milk-only Lactation Study for Patients on Eltrombopag

A Phase 4 interventional study of eltrombopag in Thrombocytopaenia, sponsored by GlaxoSmithKline. Withdrawn at 1 site in United States. Open to participants aged 4 Weeks to 26 Weeks. Per ClinicalTrials.gov, last updated 2015-05-13.

Sponsored by GlaxoSmithKline · Phase 4 and Interventional

Why this study was withdrawn
Protocol opened to recruitment in Nov 2009. No potential subjects identified in 5 years; therefore, study was terminated in Jul 2014 due to lack of feasibility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
4 Weeks to 26 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
52nd of 53
0 · median 40
Started
2013
with 5 others
Phase 4
3 of 53
none open now
Registered
19th of 53
by date
Lead sponsor
16 of 53
GlaxoSmithKline

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one is the 52nd largest by enrollment, is one of 6 that started in 2013, is one of 3 in phase 4, and was the 19th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 4 Weeks to 26 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

This is a Phase IV study to evaluate eltrombopag concentrations in breast milk of nursing mothers taking marketed eltrombopag (PROMACTA®). Up to 10 subjects (mother-infant pairs) at as many as 10 study centers in the US will be enrolled. Nursing mothers who are registered with the PROMACTA Pregnancy Registry will be offered the option to participate in this trial if they continue to take commercial eltrombopag post-delivery and decide to breastfeed their infant. Information will be collected in a diary. Breast milk samples will be collected before and after infant feedings for a 24 hour period after eltrombopag dosing to evaluate the eltrombopag concentrations in the breast milk. Mothers will also be given the option to have a pharmacokinetic (PK) blood sample collected from the infant.

03

Conditions studied

  • Thrombocytopaenia

Keywords

  • eltrombopag
  • pharmacokinetics
  • PROMACTA
  • lactation
  • milk-only study
04

Who can participate

Ages eligible
4 Weeks to 26 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mother is registered with the PROMACTA Pregnancy Registry and meets all the enrollment criteria defined in the PROMACTA Pregnancy Registry study (113327).
  • Mother is continuing to take eltrombopag.
  • Mother has received 7 consecutive eltrombopag doses prior to the milk sample collection.
  • Infant is 4 weeks to 26 weeks of age at the time of milk sampling.
  • Exclusively breastfeeding mother-infant pair; either via breast or with expressed milk from the mother.
  • Mother is capable of giving written , which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion criteria

Exclusion Criteria:

  • Infant was born with complications that could impact ability to participate in this study.
  • Breastfeeding is not well established in the mother-infant pair (e.g., poor latching of the infant or low milk supply).
  • Infants who are supplemented with formula or are consuming solid foods.
  • Unwillingness or inability of mother to follow the procedures outlined in the protocol.
  • Mother is mentally or legally incapacitated
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Study

    Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.

    Drug: eltrombopag

Interventions

  • Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.

06

What researchers measure

Primary outcomes

  1. Breast milk eltrombopag concentrations collected from nursing mothers taking eltrombopag

    Time frame: 24 hours

Secondary outcomes

  1. AEs in infant reported during the 24 hour breast milk collection period

    Time frame: 24 hours

  2. Plasma eltrombopag concentrations from infant, as data permit (optional)

    Time frame: 1 sample within 2 days

07

Study locations

1 site
  • GSK Investigational Site
    Research Triangle Park, North Carolina 27709, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2010
First posted
Jan 25, 2010
Start
Mar 2013
Primary completionActual
Jul 2014
CompletionEst.
Jul 2014
Last update
May 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01055600
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 25, 2010
Start date
Mar 2013
Primary completion
Jul 2014
Completion
Jul 2014 (estimated)
Last update
May 13, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion